MoneyWorks4Me

Supriya Lifescience - Quaterly Results

14 Aug 2026 Evaluate
The sales figure stood at Rs. 1897.47 millions for the June 2026 quarter. The mentioned figure indicates a growth of about 30.79% as compared to Rs. 1450.74 millions during the year-ago period.Net profit of the cmpany stood at Rs. 240.43 millions for the quarter ended June 2026 a decline of -30.89% from Rs. 347.90 millions  in the same quarter last year.The company reported a degrowth in operating Profit to 501.06 millions from 543.75 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202606 202506 % Var 202606 202506 % Var 202603 202503 % Var
Sales 1897.47 1450.74 30.79 1897.47 1450.74 30.79 8278.75 6964.85 18.86
Other Income 26.48 26.74 -0.97 26.48 26.74 -0.97 114.87 98.15 17.04
PBIDT 501.06 543.75 -7.85 501.06 543.75 -7.85 3055.35 2706.11 12.91
Interest 3.74 5.12 -26.95 3.74 5.12 -26.95 18.89 16.86 12.04
PBDT 497.32 538.63 -7.67 497.32 538.63 -7.67 3031.88 2689.25 12.74
Depreciation 89.40 64.51 38.58 89.40 64.51 38.58 284.09 204.44 38.96
PBT 407.92 474.12 -13.96 407.92 474.12 -13.96 2747.79 2484.81 10.58
TAX 167.49 126.22 32.70 167.49 126.22 32.70 656.59 605.23 8.49
Deferred Tax 82.36 20.87 294.63 82.36 20.87 294.63 42.26 38.66 9.31
PAT 240.43 347.90 -30.89 240.43 347.90 -30.89 2091.20 1879.58 11.26
Equity 160.97 160.97 0.00 160.97 160.97 0.00 160.97 160.97 0.00
PBIDTM(%) 26.41 37.48 -29.55 26.41 37.48 -29.55 36.91 38.85 -5.01

Supriya Lifescience Share Price

792.20 -21.05 (-2.59%)
14-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1924.90
Dr. Reddys Labs. 1202.00
Cipla 1450.00
Lupin 2235.00
Zydus Lifesciences 1140.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: